Information  X 
Enter a valid email address

Amryt Pharma PLC (AMYT)

  Print      Mail a friend

Tuesday 07 January, 2020

Amryt Pharma PLC

PDMR Dealings

RNS Number : 0232Z
Amryt Pharma PLC
07 January 2020
 

Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them

 

 This form is required for disclosure of transactions under Article 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation)

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

 

Joe Wiley

 

 

 

 

2

Reason for the notification

 

a)

Position/status

CEO

 

 

 

 

 

 

b)

Initial Notification Amendment

Initial Notification

 

 

 

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Amryt Pharma plc

 

b)

LEI

213800YNUJEOJ8L4T95

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial  instrument,

type  of

instrument

Identification code

Ordinary shares of £0.06 each

 

GB00BKLTQ412

 

b)

Nature of the transaction  

Purchase of Shares

 

 

 

 

 

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.219

7,999 shares

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

7,999 shares

 

£9,750.78

 

 

 

 

 

e)

Date of the transaction

January 7th, 2020

 

 

 

f)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

 

 

g)

Additional Information

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHBRMTTMTMMBAM

a d v e r t i s e m e n t